Drug Trial Radar · NCT04680052
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
654
Actual
Start
Apr 15, 2021
Primary completion
Feb 23, 2024
Study completion Aug 9, 2028
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Conditions
- Follicular Lymphoma
- Marginal Zone Lymphoma
Interventions
tafasitamabDrug
tafasitamab will be administered IV for 12 cycles
rituximabDrug
Rituximab will be administered IV on cycles 1 - 5
lenalidomideDrug
Lenalidomide will be administered PO for 12 cycles
placeboDrug
placebo will be administered IV for 12 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred FirstTime frame: up to approximately 34 months
- FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred FirstTime frame: up to 2 years
Locations
261 sites in 28 countries. Site status is shown where the registry gives one.
John Muir Health Clinical Research Center
Concord, California
Marin Cancer Care
Greenbrae, California
The Oncology Institute of Hope and Innovation
Pasadena, California
Sharp Memorial Hospital
San Diego, California
Middlesex Hospital Cancer Center
Middletown, Connecticut
Smilow Cancer Hospital
New Haven, Connecticut
Cancer Specialists of North Florida
Jacksonville, Florida
Brcr Medical Center, Inc
Plantation, Florida
Asclepes Research Centers
Weeki Wachee, Florida
Northwest Georgia Oncology Centers,P.C
Marietta, Georgia
Straub Medical Center
Honolulu, Hawaii
Des Moines Oncology Research Association
Des Moines, Iowa
Baptist Health Lexington
Lexington, Kentucky
Norton Cancer Institute
Louisville, Kentucky
Tulane University
New Orleans, Louisiana
University of Maryland-Greenebaum Cancer Center
Baltimore, Maryland
Cancer Center For Blood Disorders
Bethesda, Maryland
Barbara Ann Karmanos Cancer Hospital
Detroit, Michigan
Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc)
Saint Louis Park, Minnesota
Hattiesburg Clinic Hematology
Hattiesburg, Mississippi
Roswell Park Cancer Institute
Buffalo, New York
Nyu Clinical Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Integris Cancer Institute
Oklahoma City, Oklahoma
Charleston Hematology Oncology Associates
Charleston, South Carolina
Prisma Health Upstate
Greenville, South Carolina
Prairie Lakes Health Care System, Inc.
Watertown, South Dakota
Texas Oncology-Baylor Charles A. Sammons
Dallas, Texas
The Center For Cancer and Blood Disorders
Fort Worth, Texas
Lyndon B Johnson General Hospital
Houston, Texas
Md Anderson Cancer Center
Houston, Texas
Renovatio Clinical
Spring, Texas
Utah Cancer Specialists
Salt Lake City, Utah
University of Virginia Medical Center
Charlottesville, Virginia
Vista Oncology Inc Ps
Olympia, Washington
Virginia Mason Medical Center
Seattle, Washington
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington
Northwest Medical Specialties Pllc
Tacoma, Washington
Eastern Health
Box Hill, Australia
Royal Hobart Hospital
Hobart, Australia
Showing 40 of 261 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.